Good morning everyone. Thank you for being here. Welcome to Donaldson Company’s Fourth Quarter and Full Year 2022 Earnings Conference Call. I will now hand the call over to Sarika Dhadwal, Director of Investor Relations. Please proceed.

Good morning. Thank you for joining Donaldson’s fourth quarter and full year fiscal 2022 earnings conference call. With me today are Tod Carpenter, Chairman, CEO, and President; and Scott Robinson, Chief Financial Officer. This morning, Tod and Scott will provide a summary of our fourth quarter performance and details on our outlook for fiscal 2023. New and beginning this quarter, we are also providing investors with a supplemental quarterly earnings presentation summarizing our results and outlook which can be found on our Investor Relations website at ir.donaldson.com. As a reminder, during today's call, we will reference non-GAAP metrics. A reconciliation of GAAP to non-GAAP metrics is provided within the schedules attached to this morning's press release. Additionally, please keep in mind that any forward-looking statements made during this call are subject to risks and uncertainties, which are described in our press release and SEC filings. With that, I'll now turn the call over to Tod Carpenter. Please go ahead.

Thanks, Sarika. Good morning, everyone. Fiscal 2022 was a challenging year given the macroeconomic and geopolitical environment. I'm really proud of the way our team rallied together in support of our mission of advancing filtration for a cleaner world. We ended the year with revenue over $3 billion, including a $1 billion contribution from our industrial business. Adjusted earnings per share were $2.68, in line with our most recent guidance. We also returned $281 million to shareholders in the form of dividends and share buybacks. We lived up to our principle of enriching our communities throughout the year and gave back, for example, donating to the relief efforts in Eastern Europe and delivering meals to our employees in Shanghai during the recent COVID-19 lockdowns. We also achieved our fiscal 2022 ESG goal of reducing our CO2 emissions by 6,000 metric tons, representing a 5% reduction from the 2019 baseline. We invested for our future across several areas, including our customers through our research and development and capacity expansions, in our long-term profitable growth through our advanced and accelerate portfolio, including acquisitions, particularly in the life sciences sector, and in our team, including the addition of new leadership positions supporting ESG and diversity, equity and inclusion. Now, on the fourth quarter, we closed the year strong. Sales were up 15%, with a pricing contribution of 12% and a negative impact from currency translation of approximately 7%. Adjusted EPS of $0.84 was up 27% versus the prior year, despite ongoing inflation and supply chain-related headwinds. Touching on pricing for a moment, as we have been discussing throughout the last several quarters, our efforts aimed at offsetting increased input costs have been one of our main focus areas. While we have made significant progress in achieving the appropriate levels of price across most of our customer base, in some areas, we have more work to do. Moving to the operational and supply chain side, the challenges we have been facing throughout the year continue. However, in the fourth quarter, we began to see some areas of stabilization, including pockets of commodity cost leveling, albeit at high levels, and a slight easing of global logistics and labor pressures. With that, we've started to move back to relocalizing our manufacturing and capitalizing on our region-for-regions strategy. Aided by these dynamics, we are seeing some reductions in our late backlogs and improvements in our fill rates. While encouraging, we view these recent trends as fragile and are cautiously optimistic regarding their sustainability. In the fourth quarter, we continued to lay the foundation for our future growth, pursuing organic and inorganic opportunities to ensure we remain the leader in technology-led filtration. In June, we announced the acquisition of Purilogics, another pearl in our string of pearls life sciences strategy aimed at creating a comprehensive solution offering across the upstream and downstream bioprocessing value chain for biopharmaceutical and food and beverage products. Purilogics' novel membrane chromatography technology platform, which provides advantages over traditional resin and bead chromatography, along with our membrane expertise, global sales, and manufacturing footprint, will allow Donaldson to bring a broad portfolio of purification tools to the market for a wide range of biologics. I'm excited to welcome the Purilogics team to Donaldson and look forward to reporting on our progress in the future. Now I'll provide some segment context on our fourth quarter sales. Total company sales were $890 million, up 15% from last year. In Engine, total sales were $620 million, up about 18%. Sales in Off-Road of $108 million were up 21%, with growth in all major regions driven by continued high levels of equipment production and significant growth in our exhaust and emissions business in Europe. On-Road sales of $35 million were up 5% from the prior year, excluding currency sales were up in all major regions with the exception of Asia Pacific, where general market weakness continues to weigh on results. Overall, On-Road growth was positive in the quarter as we began lapping the discontinuation of some directed-by equipment to a large OEM customer in North America. That said, supply chain challenges, including chip shortages, are improving more modestly in this segment and limiting growth. In Engine aftermarket, sales were $442 million, an increase of 18%. Both the OE and independent channels were up double digits. Proprietary product performance continues to be a very important driver; fourth quarter aftermarket sales of PowerCore were up 30% year-over-year, in line with performance in the third quarter. On the independent side of Engine aftermarket, we continue to build our presence and see encouraging growth rates in under-penetrated markets such as Mexico and Brazil. In Aerospace and Defense, sales of $35 million were up 21% year-over-year, with strength in replacement parts as we continue to benefit from the recovering commercial aerospace industry and market share gains. Before moving on to industrial, a comment on our Engine business in China. China Engine sales were down 6% versus the prior year and down 2% in constant currency. Overall market weakness, including that stemming from the COVID-19 lockdowns which resulted in plant closures for two weeks in the quarter, negatively impacted results. While our business in China will certainly continue to be impacted by the overall market trends, I remain optimistic and excited about our future growth prospects in the country, and we remain committed to growing share. Now turning to the industrial segment, industrial sales increased 10% to $270 million. Sales of industrial filtration solutions or IFS grew 14% to $196 million, mainly driven by industrial dust collection, new equipment, and replacement parts. Our process filtration business also delivered robust sales, benefiting from new program wins. This business hit an important milestone for the full year, delivering approximately $100 million in sales, excluding the impact from currency translation. Fourth quarter sales of Gas Turbine Systems or GTS were approximately $34 million, reflecting a 39% increase bolstered by the timing of replacement parts sales in EMEA. Sales of special applications were $40 million, down 17% as the COVID-19 shutdowns in China continued to dampen disk drive sales. Importantly, our venting product sales, which fall within special applications, were up as customers expand the use of our high-tech vents for batteries and powertrains in the auto industry. This is a key strategic area for Donaldson, given the opportunities that lie ahead in this rapidly expanding market. In conclusion, our fourth quarter sales and earnings were a high watermark in the company's history, and I look forward to carrying that underlying momentum forward into fiscal 2023. Although there are many puts and takes as we think about our outlook for 2023, which Scott will discuss in a minute, we are forecasting another year of record revenue and record earnings. Importantly, we are also expecting year-over-year gross margin expansion, in addition to a full-year operating margin, which is forecasted to be a multi-decade high. Now, I will turn it over to Scott for more details on the financials and our outlook for fiscal 2023.

Thanks, Tod. Good morning, everyone. I want to start by thanking our Donaldson employees around the globe. I am impressed with how our teams came together and once again delivered a solid year. I'm also excited about what is yet to come as we look to fiscal 2023. Before talking through the details on fiscal 2023, I will add some color to fourth quarter results. My comments to follow will focus on adjusted or non-GAAP results, which exclude charges related to the termination of our operations in Russia. These charges totaled $3.4 million pretax and include write-offs for outstanding receivables and customer-specific inventory. Also included are our restructuring charges related to the closing of our office in Russia. To summarize the quarter, sales grew 15%, operating income was up approximately 19%, and EPS of $0.84 increased 27% year-over-year. Operating margin of 14.9% was up 40 basis points versus prior year as operating expense leverage outweighed gross margin pressure, gross margin of 32.9% improved 140 basis points sequentially. However, this represents a 150 basis point decline versus prior year. While our pricing is now offsetting more persistent inflation, such as that of commodities and freight; furthermore, transitionary factors such as inefficiencies, labor turnover and training costs as well as sales mix dampened margins. Operating expenses, as a percent of sales was 18.0%, favorable by almost 200 basis points over prior year, driven primarily by leverage on higher sales. I'll now briefly talk about fourth quarter segment profitability. For the first time this fiscal year, Engine pretax profit margin at 16.6% was up 90 basis points year-over-year, as our pricing efforts throughout the year began to offset cost pressure in the segment. On the industrial side, pretax profit margin was 17.8%, up 50 basis points versus prior year, rebounding from a year-over-year decline in the third quarter. As a reminder, our three fiscal 2022 acquisitions, Solaris, PAIS, and Purilogics, fall into this segment. The integration of these three businesses is going well. We are continuing to invest in their growth and look forward to seeing them scale. Now turning to the balance sheet and cash flow statements. Our free cash flow this quarter was pressured by elevated working capital, primarily driven by higher receivables from increased sales; inventory, while still elevated, was less than a store in the quarter. We have begun to see some sequential stabilization in the global supply chain and continue to work towards increased efficiency. Fourth quarter capital expenditures were $28 million, mainly driven by investments in capacity expansion, particularly in North America. Cash conversion in the quarter was approximately 80% versus about 40% through the first nine months of the year, as we are now beginning to return to more normalized levels of conversion resulting from inventory leveling. In terms of capital deployment, we paid about $20 million on the Purilogics acquisition and returned $45 million to shareholders, with $28 million in the form of dividends and $17 million in share repurchases. Our balance sheet remains in great shape as we close the year with a net debt-to-EBITDA ratio of 0.8 times. The strength of our balance sheet, combined with ample liquidity, will allow us to continue pursuing our strategic objectives in 2023 and beyond. Now, I'll walk through our fiscal 2023 outlook. Beginning with sales, we expect our fiscal 2023 sales to be up within a range of between 1% and 5%, which includes a negative impact on currency translation of about 4%. The currency impact in both engine and industrial is expected to be similar. Also included in our sales guidance is a pricing benefit of about 6%. To add some color on pricing and sales, in fiscal 2022, the pricing impact of the second half of the year was twice what it was in the first half, as actions taken throughout the year layered in. Therefore, 2023 pricing benefits will decrease as we begin to lap the prior year's actions, resulting in stronger gains earlier in the year. For Engine, we expect a revenue increase of between 0% and 4%, driven by growth in aftermarket and aerospace and defense. We are focusing mid-single digit growth in both of these businesses while lapping strong fiscal 2022 results. In Engine aftermarket, robust demand driven by continued high levels of vehicle utilization, and market share gains in less material geographies are expected to contribute to growth. Aerospace and Defense sales are expected to be supported by the strengthening commercial aerospace industry, which still has plenty of runway and remains below pre-COVID levels. For Off-Road and On-Road, sales are forecasted to be down low single digits, due in part to the strategic exiting of certain low-margin programs in both businesses. As we think about the company's profitability and customer portfolio management, we are committed to focusing on higher-margin opportunities that better reflect the value we bring to customers and are becoming more selective in the projects we engage in. While this might have a short-term negative impact on sales, we believe this is the right strategy for increasing profits on increasing sales over time. A few other factors driving our expectations in these two businesses are; within Off-Road, our Exhaust and Emissions business is forecasting to slow as volumes related to new emissions programs are believed to have peaked in fiscal 2022, not returning to a more normal run rate. Within On-Road, sales will likely be range-bound due to continued supply chain issues including chip shortages. Now we'll walk through the industrial segment, where we expect sales growth of 3% to 7% led by strength in IFS. IFS sales are projected to increase high single digits driven by continued dust collection and process filtration product demand and contributions from our three fiscal 2022 acquisitions. GTS sales are projected to increase low single digits year-over-year. Special applications growth is forecasted to be flat versus the prior year. APAC market weakness is expected to continue to impact sales, including disk drive sales, which will likely still be pressured through the first half of the year. Now I'll move on to our margin outlook. We are forecasting an operating margin range between 14.5% and 15.1%, up from 13.5% in fiscal 2022. Operating margin is expected to be stronger in the second half of the year, driven by gross margin expansion and operating expense leverage. As we move through fiscal 2023, expense discipline will be critical for the company as we manage through a potential recessionary environment, but also strategically invest for the future. Moving to EPS, we expect the range between $2.91 and $3.07, which at the midpoint represents an approximate 11% increase versus fiscal 2022. Now onto our balance sheet and cash flow outlook. As we work towards increased inventory efficiency, we expect working capital to be a source of cash, driving cash conversion in the range of between 110% and 125%, higher than the historical average year. Capital expenditures, weighted towards our long-term growth initiatives, are forecasted to be between $115 million and $135 million, including investments in tooling and equipment for new products and technology, maintenance and infrastructure investments, capacity expansion, and continuous improvement projects for safety, quality, and margin improvement. As we think about our capital deployment framework for fiscal 2023, our priorities have not changed. We are committed to maintaining our discipline and strategic approach to M&A, with a focus on expanding in life sciences markets as well as returning capital to shareholders through dividends and share repurchases. Now I'll turn the call back to Tod.

Thanks, Scott. As we embark on the new fiscal year, I am optimistic and confident in the company's path forward. The opportunities that lie ahead, both within our current core businesses and in our newer, less mature, but higher margin businesses, are abundant, and we have the talent, capabilities and resources to capitalize on them, pushing Donaldson to the next stage of its evolution. In fiscal 2023, our investments in our customers, our people, and our communities will continue. With all of that said, I would be remiss if I did not touch on the recessionary concerns that are top of mind for all of us. At Donaldson, over our long history, we have been well positioned to withstand economic downturns, and recessions have come out on the other side, and our playbook approach has proven effective. First, cement our position as the leader in technology-led filtration by meeting customer demand as we work down our backlogs and inventory, utilizing our global and growing footprint to circumvent any supply chain issues. Second, capitalize on our more resilient businesses, such as our replacement parts and high-tech vents for batteries and powertrains. Third, judiciously manage costs to ensure our expense space aligns with our top-line results. Fourth, utilize our strong balance sheet, which allows us to invest even in an economic downturn to pursue key opportunities and strategically important areas, such as our advanced and accelerate businesses and the life sciences sector. In closing, while there is once again a lot of uncertainty heading into the fiscal year, we feel well prepared for what lies ahead and look forward to improving the company's profitability profile and adding another year of record sales and record earnings to the long history of Donaldson. Our team showed tremendous resilience in fiscal 2022, and our agility will be a key asset in fiscal 2023. Now I'll turn the call back to the operator to open the line for questions.

Thank you. Our first question comes from Bryan Blair from Oppenheimer. Please go ahead. Your line is open.

Thank you. Good morning, everyone.

Good morning.

I was hoping you could parse it out for us what you're contemplating in terms of first versus second half volume in your 2023 sales guidance? Price impact is reasonably straightforward in terms of the carryover and cadence throughout the year. You've called out potential recessionary impact. And that must be factored in some regard. I guess, to be direct, are you assuming that volume goes negative in the back half? Or was that in your current guidance?

Bryan, good morning. So we tried to take all available factors into our guidance for the year when coming up with the overall sales number. Certainly, because of the COVID situation, we're going to be lapping some easier comps in the first half of the year. So our sales growth will be much, much stronger in the first half. For the second half, if you look at the half combined, we'd have growth in both halves, although most of it in the first half of the year.

Okay. Appreciate the color. Just to level set, what was the growth of your Advance and Accelerate portfolio in fiscal 4Q and the full year? And if you have the metric on hand, where did Advance and Accelerate shake out as a percentage of total revenue for the year?

Sure, Bryan, I'll take that one. So in the fourth quarter, Advance and Accelerate was up 18% year-over-year, and it's about 60% of the total business as of the end of the fourth quarter.

Okay. Thank you. And curious if the macro uncertainty that you cited and everyone is clearly focused on, whether that has impacted your deal funnel in terms of pursuing Life Science assets, whether in terms of actionability or perhaps positively with regard to Solar expectations, bringing forward some activity at perhaps more reasonable pricing?

Yes. We would say that overall, our M&A pipeline still remains strong. It's very strategic and pointed in nature. Valuations have come down slightly within the last quarter. However, we're talking about filtration companies, and we're talking about life sciences. Both of them clearly are above industrial averages where we're targeting. So we have to be careful with them when we say it has come down slightly. Still, we view our efforts as being very strong and look forward to continued success as we completed three acquisitions in this fiscal year, and we'll continue to execute our inorganic strategy.

Understood. Thanks again.

Our next question comes from Laurence Alexander from Jefferies. Please go ahead. Your line is open.

It's Dan Rizzo for Laurence. Thank you for taking my questions. You mentioned the backlog and its current status. I was just wondering how it compares to the historical average and how much higher it is, as well as what you expect over the next 12 months.

Sure. We would say actually, the channel inventories out there have improved slightly. Our overall late backlog is down slightly. However, our backlog remains strong. And our late backlog, although slightly improved, still remains at uncomfortable levels. Our backlogs continue to be quite nice.

You mentioned the lockdowns in China, which is quite obvious, but as we come out of that situation, are things meeting expectations? Or is the recovery more gradual than we would have expected, say, two months ago? Or is it going according to plan?

Yes, that's a great question. We are being a bit more cautious regarding the outlook for China and what we understand; we have certainly incorporated this into our guidance. However, I would say that we are taking a more conservative approach concerning China, based on our experiences there.

If we consider the Aftermarket business during the recession, looking back at 2008 or the industrial slowdown in 2016, do Aftermarket sales decline, or do they still remain somewhat positive in terms of volumes?

Overall vehicle utilization across the world right now still remains very positive and very heavy. So we would tell you the market growth opportunities are still prevalent from just overall utilization and end market strength. But also, Donaldson has underrepresented geographies where we have additional growth opportunities that we continue to pursue, and we look to have success over the quarters ahead.

Right. Thank you very much.

Our next question comes from Dillon Cumming from Morgan Stanley. Please go ahead. Your line is open.

Hey, good morning, guys. Thanks for the question. I just wanted to put maybe a finer point around the original kind of revenue question that was asked first. I mean, obviously, the guidance does imply that volumes are down, right, you kind of back out the pricing and the FX headwinds that you guys mentioned. I guess, would your response to that just be that you're still kind of embedding a general level of conservatism, and maybe that's reflective of some of those product line exits in the Engine segment? Or do you feel like you're actually seeing that materialize in the order book? So I guess from my perspective, it feels like you're still signing a pretty bullish tone on the overall end market backdrop. So just curious if that negative implied volume guidance is actually reflected in your kind of order trends to date?

Sure. If you look at Engine OE, what we're looking at with the OEM sectors is U.S. up, rest of the world more moderated. But we have a couple of headwinds there, roughly a little bit more than 1%, where we have done some product management. We've walked away from some business, but also on our Exhaust and Emissions business, we will see a decline there because last year, we had the benefits of some prebuy. So you get about a little bit more than 1% based upon those choices from Donaldson Company. And then the rest of the world, actually, you really start to feel it over in Japan, where you have some volume moderation, but very heavy FX hit. And in Europe, where you have some volume moderation and also a very heavy FX hit. So you couple all those factors into the Engine OE side of our business, and that's how you get the more careful base guide. And I do want to stress that we are being careful relative to the outlook in China as well.

Okay. That makes sense. Thanks, Tod. And then maybe just switching over to Europe for a second. Just curious what you guys are seeing in terms of your production footprint over there. I mean, obviously, the energy situation is still pretty volatile. But just curious if that's kind of impacting your ability to produce or if you kind of factor any level of cost inflation on that side of the Europe portfolio in fiscal 2023?

Yes. Looking across our Aftermarket segment, we will not have revenue from Russia compared to last year, which will be a headwind of around 1%. Please keep this in mind when considering Europe. Overall, we would say that Europe is doing reasonably well. There’s a slight increase in caution and moderation, but the business remains strong and positive. We haven't observed significant pullbacks in incoming order activities. It seems to be just a bit more careful at this time, and we are closely monitoring the situation.

Okay. That's helpful. And then just last one for me. In terms of the 6% pricing that you guys guided to, I guess, would you kind of characterize that as just reflective of the carryover that you've had from kind of pricing actions to date? Or is there still scope for you to kind of go out there in the market, particularly in the independent channel, maybe put out some further pricing actions as the year progresses?

Yes. Dillon, this is Scott. So we said 6% for the year. The majority of that relates from carryover from all the prices that we've layered in this year, which will obviously have a bigger impact in the first half than in the back half. We're still going to go out with our typical standard increases that we would normally do on each year. We still have continuing labor cost increases and other cost increases we're going to have to deal with. But the majority of it would be from this year with a few limited actions next year that will also contribute.

Yes, I would say that in the independent Aftermarket channel, we have returned to a more normal behavior. If inflation remains at its current levels, we expect to continue this trend throughout the upcoming year.

Okay. Got it. Thanks for the time.

Our next question comes from Brian Drab from William Blair. Please go ahead. Your line is open.

Hi, thanks. I just want to clarify on the revenue growth for the year. When you said a second ago, Tod, that Russia is a 1% impact, that's on a consolidated basis, right?

Yes, absolutely. Overall, it's 2% when looking at previous years for the company. However, last year it was closer to 1% because we had recognized some revenue before the conflict in Eastern Europe began.

Okay. But in terms of year-over-year impact in fiscal 2023, saying it's about a one point headwind?

Yes.

Okay. Got it. So when we take the guidance of 1% to 5% and price FX is a net 2%, volume has been down 1% to the range of negative 1% to positive 3%. So ex-Russia, that range is basically 0% to 4%.

Yes.

Which segment is being impacted the most, Russia? I know we discussed some of the food and beverage operations that you were involved in or are currently winding down in Russia. Is the impact greater on the industrial side?

Engine. And specifically, Engine Aftermarket.

Okay. And is that true that you have some in the industrial side, though, in food and beverage? And you mentioned some baby food processing, etc. Is that just more minor relative to what you're doing with Engine?

Right. We did have some on the industrial side within food and beverage, yes. But it's largely an Engine story.

Okay. And if you aggregate the revenue, I don't know if you've been able to give us your revenue for all the acquisitions precisely. But is that revenue material or immaterial to the revenue for growth for 2023?

Yes, it's relatively immaterial.

I mean, is it less than $20 million, Scott? Can you give us any ballpark if you add all three of them up?

It's in that range.

Okay. All right. And then the last question I'll just ask is, you're talking about strategically moving away from some lower margin business. A couple of years ago, you had the operating margin target, which I guess we're already beyond the year for which you gave that target of like 15% to 15.8%. I'm just curious if like that 15.8% high end of the range, potentially goes up over the longer term as you move away from this low margin business?

Yes. So I mean, we got to 14.9% this quarter, which was just within a hair of 15%, which would have been a great number, but 14.9% is still a solid improvement. We expect to increase that again next year with our guidance of 14.5% to 15.1%. So for the year, we expect to continue to improve the operating margin. We're committed to higher levels of profitability on higher sales. We have to continue to leverage the company, invest in higher margin projects that mix the company up and continue to operate efficiently. We're going to continue to push the balance of our operating margin horizon because we feel as we continue to grow the company, we can leverage our OpEx and bring in higher than average margin opportunities. So we do expect to have an Investor Day next spring. We're working on planning that now we'd like to invite you all to come to beautiful Bloomington, Minnesota and see our headquarters, and we'll have more to say about that then.

Did you consider moving away from the low margin business back in April of 2019 when you presented that slide? Or is that a new element of your strategy since then?

No. Brian, we had that in 2019. And actually some of it was in flight. It's not an easy pivot when you walk away from some of the businesses, especially on the OE base that we've been talking about. So those are multiple quarter-based products when we end up doing that with our customer base.

Okay. Thanks very much.

Our next question comes from Rob Mason from Baird. Please go ahead. Your line is open.

Yes, good morning. Could you speak to what your expectations are around the Advance and Accelerate portfolio for 2023 relative to your 1% to 5% overall sales guidance?

Yes. I mean, we continue to want to invest in our Advance and Accelerate portfolio that currently represents 62% of the company. And when we think about our investments, we're always asking ourselves, are we driving our investments to the right portion of our strategy and to the right portion of our company? Certainly, our opportunities there are going to drive our revenue growth. This year was probably a little bit unusual with 30% growth local currency in the fourth quarter in Off-Road and almost 30% in local currency for the full year. We had some really strong growth in certain pieces of our portfolio. But longer term, our growth will be driven by our Advance and Accelerate portfolio, and you can see that coming through in our guidance in Off-Road and On-Road this year.

Yes. Just on that point, would you have the number of what the Exhaust and Emissions contributed to Off-Road this past year, say, 29% overall?

Between 3% and 4% of total company revenue.

Okay. Also just, you've spoken about the moderation and some raw material prices. What's sort of built into the gross margin expectation, gross profit expectation for the year in terms of raw materials? Will that actually be still a year-over-year headwind? Or does that provide any relief?

Yes. I mean, we would expect relatively consistent levels of cost this year. We're committed to adjusting our prices if certain costs continue to spike or something happened that would drive an unusual cost increase. But we're planning for relatively consistent commodity pricing this year in our gross margin analysis.

Okay. Sure. Just last question. Purilogics, the acquisition that was completed during the quarter. I'm just curious, I understand that's small and it's early stage. But how should we be thinking about that business ramping over the next few years? And specifically, I'm curious if as you've done your due diligence there, identified areas they're already spec'd into either vaccines, therapeutics success those may have in clinical trials. I'm just curious what kind of visibility you have on that business.

Sure. It brings in a differentiated membrane chromatography technology to the company. So if you think overall about the media that Donaldson uses, we are very good and strong at membrane-based activities. This allows their technology and our membrane experience to really combine and go forward. They have patents as well as some important trade secrets, and formulations that all have been proven out in our laboratories prior to the acquisition. They really focus on cutting-edge applications such as they'll be applicable in mRNA and pDNA and ion exchange and other affinity-based separation opportunities. They are already working with over 15 biopharmaceutical manufacturing companies. While this is a bit of a longer cycle opportunity because they are pre-revenue, Donaldson's strength of the balance sheet, we'll certainly be able to help leverage that company forward. We look forward to really great growth over the years ahead.

Great. Thanks a lot.

Our last question comes from Nathan Jones from Stifel. Please go ahead. Your line is open.

Good morning. This is Adam Farley on for Nathan. I wanted to follow up on the strategic exiting of lower-margin programs in On- and Off-Road. Are these exits complete? Or should we expect this to be an ongoing process with maybe more to come in 2023?

The one that we've been talking about for the past four quarters, that one is complete. We've lapped it now with the reporting of the fourth quarter. But obviously, it did have a considerable headwind in the year. So that is behind us. However, we continue to look at our portfolio, particularly in light of the inflationary pressures that we felt throughout the balance of the year. That's just standard work for us now. We'll continue to take a look at low-margin-based products. Frankly, if we're not getting paid for our technology, we have choices to make. We consider that standard work looking forward.

Okay. And then turning to CapEx. CapEx is stepping back up to the $115 million to $135 million range. Can you provide some color on where you're deploying that capital organically? And maybe are some of these CapEx-related items related to projects from 2022 that maybe got delayed due to supply chain?

Yes. As you mentioned, we have a projected CapEx range of $115 million to $135 million. We are coming off a lower year, and there were delays in our CapEx plans that caused some projects to move from this year to next year. Looking ahead to our CapEx for next year, we anticipate about 75% will be for growth and 25% for maintenance. The growth portion will focus on increasing capacity and developing new products. We believe these are strong investments that will yield favorable returns for the company and support our goal of maintaining a solid return on invested capital.

Thank you for taking my questions.

Thank you.

We have no other questions. I'd like to turn the call back over to Tod Carpenter for closing remarks.

That concludes today's call. I'd like to thank everyone who participated, and I look forward to reporting our first quarter results in late November. I also look forward to hosting all of you in the spring at the Investors Day that we'll be holding with more information to come regarding that. Have a great day. Goodbye.

This concludes today's conference call. Thank you for your participation. You may now disconnect.